The National Institutes of Health (NIH) is inviting applications for the Specialized Programs of Research Excellence (SPOREs) in Human Cancers, specifically for the fiscal years 2027, 2028, and 2029, under the P50 Clinical Trial Required grant program. This initiative aims to fund innovative translational research that enhances prevention, early detection, diagnosis, and treatment of organ-specific cancers or closely related cancer groups, utilizing advanced cellular, molecular, and genetic approaches. With an estimated total program funding of $25 million and the expectation of awarding 12 grants, interested applicants must submit their proposals by January 25, 2027, with the anticipated award date set for June 4, 2027. For further inquiries, applicants can contact Bradley T. Scroggins at bradley.scroggins@nih.gov or by phone at 240-276-7860.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). This is a re-issuance of PAR-23-284. The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this NOFO, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or epigenetics. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.

Division of Cancer Treatment and Diagnosis/National Cancer Institute

Buyer

Eligible Applicants

Funding Category

Funding Instrument

Opportunity Category

Cost Sharing or Matching Requirement

Original Source